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Abstract
Membrane proteins (MP) constitute 20–30% of all proteins encoded by the genome of various organisms and perform a wide
range of essential biological functions. However, despite they represent the largest class of protein drug targets, a relatively small
number high-resolution 3D structures have been obtained yet. Membrane protein biogenesis is more complex than that of the
soluble proteins and its recombinant biosynthesis has been a major drawback, thus delaying their further structural characteri-
zation. Indeed, the major limitation in structure determination ofMP is the low yield achieved in recombinant expression, usually
coupled to low functionality, pinpointing the optimization target in recombinant MP research. Recently, the growing attention
that have been dedicated to the upstream stage of MP bioprocesses allowed great advances, permitting the evolution of the
number of MP solved structures. In this review, we analyse and discuss effective solutions and technical advances at the level of
the upstream stage using prokaryotic and eukaryotic organisms foreseeing an increase in expression yields of correctly foldedMP
and that may facilitate the determination of their three-dimensional structure. A section on techniques used to protein quality
control and further structure determination of MP is also included. Lastly, a critical assessment of major factors contributing for a
good decision-making process related to the upstream stage of MP is presented.
Keywords Production . Membrane protein . Host . Codon usage . Protein 3D-structure . Structure determination . Quality
control . Optimization
Recombinant membrane protein biosynthesis
Membrane proteins (MP) constitute 20–30% of all proteins
encoded by the genome of various organisms (Lantez et al.
2015) and perform a wide range of essential biological func-
tions, thus representing the largest class of protein drug targets
(Bernaudat et al. 2011). However and despite their biological
relevance, most of these targets still do not have any assigned
function (Bernaudat et al. 2011), as reflected by the relatively
low number of MP structures recorded in Stephen White’s
laboratory database (http://blanco.biomol.uci.edu/mpstruc/)
—876 unique MP structures in March 2019. Indeed,
determining the structure of a MP is quite complex, mostly
due to problems arising fromMP low natural abundance, their
toxicity when overexpressed in heterologous systems, and
difficulties in purifying stable functional proteins and
obtaining well-diffracting crystals (Gul et al. 2014; Lantez
et al. 2015). To cope with MP low natural abundance that
limits subsequent structural and functional studies, four differ-
ent approaches have been proposed (Popot 2018), namely (1)
overexpression in vivo and in situ; (2) overexpression in vivo
in inclusion bodies; (3) cell-free expression (CFE) in vitro; (4)
chemical synthesis for short MP or MP fragments. Here, we
will generally address the first two approaches based on the
following host cells: Escherichia coli (E. coli),Pichia pastoris
(P. pastoris), also known as Komagataella phaffii, mammali-
an cell lines. The process to obtain a recombinant protein
involves the synergy of three key elements—a gene, a vector,
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and an expression host—(Bernaudat et al. 2011) and, at least
at the theoretical level, is straightforward (Rosano and
Ceccarelli 2014). In practice, many things can go wrong,
and distinct problems can be found including poor growth of
the host, inclusion body formation, or lack of protein biolog-
ical activity (Rosano and Ceccarelli 2014). Indeed, targeting
an overexpressed MP to a membrane in such a way they can
insert and achieve its native structure is far from being an easy
task, once they tend to be toxic, leading to low expression
yields of often misfolded and aggregated MP (Popot 2018;
Rajesh et al. 2011). Moreover, the high diversity of structures
and physico-chemical properties displayed by MP makes un-
feasible to accurately predict if a protein of interest will ex-
press well, be easy to purify, and be biologically active or
crystallize in any given experimental protocol (Bernaudat
et al. 2011). Based on the exposed, the development of im-
proved strategies in the recombinant MP production pipeline
foreseeing to increase their expression yields in a correctly
folded form is crucial in MP research. The evaluation of pu-
rified protein quality is crucial in any protein production pro-
cess and should be accurately performed to avoid irreproduc-
ible and misleading observations in the subsequent studies
(Raynal et al. 2014). After production, MP need to be effi-
ciently solubilized (recently reviewed by Hardy et al. 2018
and Popot 2018) and purified (Pandey et al. 2016), from
which their quality in terms of purity, homogeneity, activity,
and structural conformity should be assessed (Oliveira and
Domingues 2018; Raynal et al. 2014). In this review, generic
guidelines and host characteristics aiming an accurate choice
of the host expression system that better suits particular needs
will be initially overviewed in this review, and then we discuss
important advances reported at the level of the upstream stage
of recombinant MP production processes using E. coli, P.
pastoris, and mammalian cell lines, representative of major
expression systems used for protein expression.
Subsequently, general techniques to perform the quality con-
trol of the target protein are presented and at the end, insights
and directions for a successful MP production pipeline are
shown.
Economics vs complexity: guidelines
to choose the right host
The most common systems for MP overexpression are
microbial (bacteria or yeasts) or higher eukaryotes (insect
or mammalian cells) [reviewed in (Bernaudat et al. 2011;
Fernández and Vega 2016; He et al. 2014; Midgett and
Madden 2007; Wagner et al. 2006)]. There is no such a
perfect host that suits all MP expression projects once
they all have advantages and limitations, as highlighted
in Table 1. Moreover, the reasons why some MP are
overexpressed but others are expressed at low levels are
not fully known, although it can be related to how diffi-
cult is to fold MP into a functional state (Andréll and
Tate 2013).
In terms of increasing complexity, the expression systems
can be grouped as follows: bacteria < yeasts < insect cells <
mammalian cell lines. With an increasing complexity, there is
generally an increase in the ability of the host cell to perform
native post-translational modifications (PTM). As such,
heavily glycosylated proteins are expected to be produced in
a more native and folded form frommammalian cell lines, and
those obtained from yeasts may not present the native glyco-
sylation profile. On the other hand, simpler hosts such as bac-
teria allow high productivities, and combine the speed with
easiness of operation at a lower cost.
Requirements in terms of specific PTM or a near-native-
like environment for some mammalian MP are usually the
factors dictating the choice of mammalian cell lines, which
usually makes use of human embryo kidney (HEK) and
Chinese hamster ovary (CHO) cell lines and both cell lines
can be applied in stable and transient transfections (He et al.
2014; Lyons et al. 2016). The process of recombinant pro-
tein production by transient expression involves the genera-
tion of plasmid, transfection in log phase, optional feeds
from 24 h onwards, and then harvest from 48 h to 14 days,
depending on the target protein, cell line, and culture condi-
tions applied (McKenzie and Abbott 2018). Contrasting with
transient expression, stably transfected cell lines takes more
time (months) and usually requires the stable integration of
the recombinant DNA into the host cell genome. Since the
expression vector has a gene conferring resistance to an
antibiotic, stable integrants can be identified by antibiotic
selection; moreover, the integration of the gene into the host
genome may be random or the host cell can be engineered
to contain a specific sequence recognized by a recombinase
that allows targeted integration. Selection of clonal cells is
additionally required to identify highly expressing cell lines
that are stable under prolonged culture (Andréll and Tate
2013). Transient transfection is quick but after scaling-up,
batch-to-batch variability in the amount of protein expressed
is often observed; on the other hand, although stable gene
expression is initially slower and more technically challeng-
ing once a clonal cell line is generated, long-term overex-
pression can be much more consistent, and the purification
of large quantities of supercoiled plasmid DNA for transient
expression is not required (Chaudhary et al. 2012; Andréll
and Tate 2013). Despite the slow growth rate and usually
higher cost, the number of MP structures generated based on
such systems has considerably increased, being foreseeable
that with the increasing use of cryo electron microscopy for
structure determination wherein lesser amount of sample is
required (e.g., in comparison with crystallographic studies),
mammalian systems will be more frequently used (Lyons
et al. 2016).
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Other interesting features to be considered when
selecting a host: (1) native intracellular localization of
the target protein; proteins that function in specific eu-
karyotic organelles such as mitochondria, chloroplasts,
and peroxisomes will generally benefit from expression
hosts that possess such organelles (Fernández and Vega
2016); (2) types of lipids of host membranes; hydropho-
bic mismatch may occur due to differences in lipid bi-
layer composition and thickness between hosts, as
highlighted for the overexpression of eukaryotic MP in
bacteria, where the absence of sterols, sphingolipids and
poly-unsaturated fatty acids in E. coli bilayers poses
additional challenges to their proper folding (Snijder
and Hakulinen 2016); (3) Construct size; proteins larger
than 120 kDa are difficult to be efficiently expressed in
E. coli, and are typically obtained in very low yields, as
inclusion bodies or proteolytically degraded (Fernández
and Vega 2016).
To overcome the limitations displayed by these in vivo
expression systems—toxicity, limited membrane space for
MP functional folding and inefficient transport, and mem-
brane insertion mechanisms—CFE systems have been re-
ported, which rely on the use of prokaryotic and eukary-
otic protein synthesis machinery and related elements to
direct protein synthesis from added DNA or mRNA tem-
plates (He et al. 2011; Henrich et al. 2015; Zheng et al.
2014). In a different way, the preparation of highly hydro-
phobic peptides representing functional parts of MPs fore-
seeing their application onto structural and functional
s tudies can be at ta ined via chemical synthes is
(Baumruck et al. 2018). Previously, Fernández and Vega
(2016) reported some recommendations on which expres-
sion host use for a particular protein.
Upstream strategies to improve membrane
protein expression levels and/or folding
Membrane protein research strongly relies on recombi-
nant production, which is vital for obtaining high quan-
tities of properly folded proteins for further biophysical
and functional testing. While it is difficult to define a
set of guidelines generally applicable to all MP, here,
we review distinct strategies (according to Fig. 1) that
have been used to increase MP expression and/or fold-
ing using E. coli, P. pastoris, and mammalian cell-based
systems (Summarized in Tables S1, S2 and S3 in
Electronic Supplementary Information).
Escherichia coli
Escherichia coli expression systems have been largely
investigated for recombinant protein production process-
es, although with a lower success rate for membrane
proteins than for soluble proteins. Aiming to reverse
this trend, researchers have driven their efforts to devel-
op enhanced upstream stages encompassing optimiza-
tions at the genetic-level, strain engineering, or culture
conditions, which are reviewed in Table S1 (Electronic
Supplementary Information).
Genetic-level strategies
The expression of proteins outside their original context can
pose additional constraints since they might contain codons
that are rarely used in the desired host, come from organisms
that use non-canonical code, or contain expression-limiting
regulatory elements within their coding sequence. The genetic
Fig. 1 Overview of the topics
included in this review amenable
to optimization and, thus, relevant
for obtaining a successful strategy
for recombinant MP biosynthesis
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code contains 61 nucleotide triplets (codons) to encode 20
amino acids and 3 codons to terminate translation, and such
degeneracy enables many alternative nucleic acid sequences
to encode the same protein. Moreover, the frequencies with
which different codons are used vary significantly between
different organisms, between proteins expressed at high or
low levels within the same organism, and sometimes even
within the same operon (Gustafsson et al. 2004; Welch et al
2011). Indeed, each organism seems to prefer a different set of
codons over others, a phenomenon termed as codon bias
(Quax et al. 2015). Based on these observations, metrics for
the frequency of optimal codons were proposed, such as the
commonly used codon adaptation index (CAI). The CAI for a
certain organism is based on the codon usage frequency in a
reference set of highly expressed genes, such as the ones
encoding ribosomal proteins and the CAI for a specific gene
can be determined by comparing its codon usage frequency
with this reference set (Sharp and Li 1987; Quax et al. 2015).
Different codon biases are also correlated with the amount
of the corresponding tRNAs, which vary between organisms;
for example, eukaryotes commonly use the AGG codon for
arginine, although it is rarely used in E. coli (Gustafsson et al.
2004). If this exerts a negative effect on heterologous gene
expression, then the use of the use of E. coli strains overex-
pressing rare tRNAs (which are commercially available) can
improve the yields of target proteins, as previously shown for
different constructs of connexin carboxyl-terminal domains
attached to their 4th transmembrane domain (Kopanic et al.
2013).
Moreover, the more codons that a gene contains that are
rarely used in the expression host, the less likely it is that the
heterologous protein will be expressed at reasonable levels
and low levels are exacerbated if the rare codons appear in
clusters or in the N-terminal. A strategy to overcome this
problem involves sequence re-design by changing the rare
codons to codons that more closely reflect the codon usage
of the host without modifying the amino acid sequence of the
encoded protein (Gustafsson et al. 2004). Automated codon
optimization algorithms have been developed to design cod-
ing sequences optimized for increased expression in certain
hosts and codon optimization services are currently offered by
DNA synthesis companies, which often rely on confidential
algorithms. These algorithms optimize codon usage by max-
imizing a gene’s CAI to match that of the expression host,
along with optimizing for some sequence features such as
GC content and avoidance of repeats and motifs such as ribo-
nuclease recognition sites, transcriptional terminator sites,
Shine-Dalgarno-like sequences, and sequences that lead to
strong mRNA secondary structures (Quax et al. 2015). On-
line tools to gene design such as the OPTIMIZER (http://
genomes.urv.es/OPTIMIZER/) (Puigbò et al. 2007) or to an-
alyze codon usage including the CAIcal (http://genomes.urv.
cat/CAIcal/) (Puigbo et al. 2008) are currently available,
among many others which make use of distinct optimization
parameters (reviewed by Angov 2011; Gould et al. 2014;
Parret et al. 2016).
Based on the rationale that changes in protein structure and
function can occur after synonymous codon replacement and
that protein structure is DNA sequence-dependent, alternative
approaches for synonymous codon design such as the Bcodon
harmonization algorithm^ have been proposed, which adapts
the codons in a way that the original codon landscape of the
gene in the original host is maintained in the expression hosts
(Angov et al. 2008; Quax et al. 2015). The authors considered
that protein synthesis and folding in E. coli is co-translational
and that nucleotide sequence-dependent modulation of trans-
lational kinetics might influence nascent polypeptide folding.
Therefore, in this approach, synonymous codons from E. coli
were selected that match as closely as possible the codon
usage frequency used in the native gene, unless empirical
structure calculations show that the codons are associated with
putative link/end segments which therefore should be trans-
lated slowly (Angov et al. 2008). Claassens et al. (2017) stud-
ied the performance of this codon harmonization algorithm
and compared with the wild-type variant and optimized gene
variants (resorting to proprietary GeneOptimizer algorithm
from GeneArt) using different proton-pumping rhodopsins
and enzymes from archaea, bacteria, and eukarya. Codon har-
monization was performed using a codon harmonizer tool
(http://codonharmonizer.systemsbiology.nl) based on the
harmonization algorithm initially proposed by Angov et al.
(2008), and uses the codon usage frequency tables for the
native and expression hosts, based on all codons in the
protein-coding genes annotated in NCBI genome assemblies
as inputs. The Bcodon frequency landscapes^ were generated
and were evaluated quantitatively based upon a proposed
Codon Harmonization Index (CHI), in which a value close
to 0 indicates a well-harmonized gene; all harmonized variants
have a CHI < 0.1 while all codon-optimized and wild-type
variants deviate further from the native codon landscape and
consequently present CHI higher than that of harmonized var-
iants (> 0.183). It was additionally observed that transcription-
al tuning (in this case by changing the concentration of L-
rhamnose) generally improves heterologous production of
the distinct variants, although the concentration of rhamnose
frequently differs among different codon usage variants of the
same protein. In general, harmonization is beneficial for in-
creasing membrane-embedded production compared to wild-
type variants for some proteins, for which in this study, the
wild-type CHI score is also highest (as in the case of
leptosphaeria rhodopsin, CHI = 0.279). Moreover, when the
codon landscape of the wild-type gene in E. coli largely devi-
ates from the landscape in the native hosts, harmonization
seems to be a promising approach for increasing MP produc-
tion (Claassens et al. 2017). Recent developments point out
that irrespective the algorithm used, using a bicistronic design
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(in comparison with a monocistronic design) does improve
protein production in E. coli as it may eliminate the translation
initiation as the rate-limiting step of the translation process
(Nieuwkoop et al. 2019). It should be also remarked the im-
portance of using updated codon usage tables. In this way,
Athey et al. (2017) reported a database (available at hive.bio-
chemistry.gwu.edu/review/codon) aiming to present and ana-
lyse codon usage tables for every organism with public avail-
able sequencing data, and which is being routinely updated to
keep up with the continuous flow of new data.
Instead of whole sequence optimization, synonymous co-
don substitutions in the region adjacent to the AUG start may
lead to significant improvements in expression, thus
circumventing the need to consider whole sequence optimiza-
tion (Nørholm et al. 2013). Indeed, codon usage optimization
of the N-terminal guarantee an efficient translation start,
which have been proved to enhance human tetraspan vesicle
protein/TVP) Synaptogyrin 1 expression in E. coli (Löw et al.
2012). Recently, Saladi et al. (2018) developed a data-driven
statistical predictor named BIMProve,^ which combines a set
of sequence-derived features resulting in an IMProve score.
As this value increases, there is also an increase in the proba-
bility of success, i.e., selecting a MP that expresses in E. coli.
Currently, the characterization of an integral MP involves the
identification and testing of multiple homologs or variants for
expression and the predictive power of BIMProve^ enables to
enrich for positive outcomes by 2-fold by providing a low-
barrier-to-entry (Saladi et al. 2018).
Throughout the years, codon optimizations have been per-
formed on a first screening basis aiming an increase in the
yields of properly folded MP, and with much success without
noticeable changes in protein structure and function.
However, the increasing understanding of the principles of
codon bias andmechanisms of translation have been unveiling
yet unknown features. In fact, synonymous codons are known
to potentially affect protein expression at various levels and
increasing evidences have been showing that translation is
affected, leading to dramatic alterations in the conformation
and processing of some proteins (Mauro 2018). Overall, co-
don optimization seems appropriate for some applications,
e.g., protein evolution and increasing the expression and/or
activity of industrial enzymes; however, for recombinant ex-
pression of proteins for therapeutics, we should also aim to
maintain the conformation and processing of the natural pro-
tein sequences (Mauro 2018).
In E. coli and due to the higher copy number of the target
gene usually achieved with plasmid-based systems, recombi-
nant proteins are typically expressed in E. coli from medium
to high plasmid copy number (PCN) based on a Col1E-
derived origin of replication, (Baneyx 1999). The PCN is cor-
related with the recombinant gene dosage and can be accu-
rately determined by quantitative Polymerase-Chain Reaction
(qPCR) procedures (Lee et al. 2006; Martins et al. 2015). A
recent study by Jensen et al. (2017) provided a systematic
approach to identify gene disruptions that increaseMP expres-
sion in E. coli and can be used to improve expression of any
protein that poses a cellular burden.
Based on the combination of some the above-mentioned
strategies, namely, Bcodon harmonization,^ use of low copy
number vectors with moderate strength, suitable leader se-
quences, and optimization of cell culture conditions, increased
targeting to E. coli outer membrane ofChlamydia trachomatis
major outer membrane protein was observed and the forma-
tion of inclusion bodies avoided (Wen et al. 2016). On the
other hand, prokaryotic expression vectors using the rhaB
promoter which are almost completely repressed until induced
can be suitable for the expression of toxic proteins (Giacalone
et al. 2006).
Strain engineering
Remarkable enhancements in MP expression from E. coli-
based systems have been achieved with engineered strains
due to their improved ability to cope with MP-induced toxic-
ity, more efficient chaperone pathways, different substrate up-
take rates, or reinforced integrity of intracellular structures,
e.g., periplasmic space. Earlier observations have shown that
protein (including but not limited to MP) overexpression driv-
en by the T7 RNA polymerase inE. coliBL21 (DE3) cells can
be limited or prevented by cell death (Miroux and Walker
1996). In this regard, by plating E. coli BL21 (DE3) cells
expressing toxic proteins (oxoglutarate-malate carrier protein
from mitochondrial membranes and subunit b of bacterial F-
ATPase) in agar plates containing IPTG (for a review of these
methods, please refer to Schlegel et al. 2017), Miroux and
Walker (1996) were able to isolate two survivors, the mutant
host strains C41 (DE3) and C43 (DE3), which have become
known as the BWalker strains^ and widely used for MP over-
expression. Latter studies showed that mutations in the
lacUV5 promoter governing expression of T7 RNA polymer-
ase are the key to improvedMP overexpression characteristics
of C41 (DE3) and C43 (DE3) strains (Wagner et al. 2008).
The rationale behind the application of BL21 (DE3) for pro-
tein production was that T7 RNA polymerase transcribes
faster than E. coli RNA polymerase and more mRNA results
in more overexpressed protein. However, for most MP, strong
overexpression leads to the production of more protein than
the Sec translocon can process, thus impairing their insertion
into the membrane, which thereby highlights the need to tune
MP expression aiming to avoid Sec saturation (Wagner et al.
2008). Based on these observations, Wagner et al. (2008)
engineered a new BL21 (DE3) derivative strain designated
Lemo21 (DE3) wherein the activity of the T7 RNA polymer-
ase can be precisely controlled by its natural inhibitor T7
lysozyme, which plasmid was under the control of the well-
titratable rhamnose promoter (Wagner et al. 2008; Schlegel
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et al. 2012). The expression of insertase YidC fused to GFP in
the cytoplasmic membrane of Lemo21 (DE3) strain was max-
imal at 1000 μM rhamnose, and was additionally demonstrat-
ed that this strain is compatible with auto-induction media
(Schlegel et al. 2012). More recently, Baumgarten et al.
(2017) isolated the mutant56 (DE3) [Mt56 (DE3)] from
BL21(DE3) expressing YidC C-terminally fused to GFP,
which allows to evaluate if the produced proteins are being
targeted to the cytoplasmic membrane. The authors found that
this strain produced several MP in higher levels than C41
(DE3), C43 (DE3), or BL21 (DE3), and its improved perfor-
mance attributed a mutation in the gene encoding T7 RNA
polymerase in position 305 (C:G–A:T transversion), leading
to a single amino acid exchange in T7 RNA polymerase
(A102D). Rather than lowering T7 RNA polymerase levels
[as with C41 (DE3) and C43 (DE3)], the A102D mutation
weakens the binding of the T7 RNA polymerase to the T7
promoter governing target gene expression (Baumgarten
et al. 2017).
Envisaging an increase in the amount of membrane-
embedded and correctly folded mammalian GPCRs (G
protein-coupled receptor), Skretas et al. (2012) screened li-
braries of genomic fragments using two different flow cyto-
metric assays, namely, by monitoring the binding of a fluores-
cently labeled ligand to active GPCR and the fluorescence of
GPCR-GFP fusions. These screens allowed the isolation of
the genes nagD (encoding the ribonucleotide phosphatase
NagD), nlpDΔ (encoding a C-terminal truncation of the pu-
tative outer membrane lipoprotein NlpD), and the three-gene
cluster ptsN-yhbJ-npr (encoding three proteins of the nitrogen
phosphotransferase system) and was additionally proved that
their co-expression leads to a marked increase of membrane-
integrated and well-folded GPCR and also a prokaryotic MP
(Skretas et al. 2012). In general, it seems that the enhanced
effect is not due to a direct interaction of these genes with the
target proteins, but instead by indirect effects, namely, induc-
tion of stress responses or changes in the composition of the
bacterial periplasm (Skretas et al. 2012). Foreseeing the iden-
tification of genes whose co-expression can supress MP-
induced toxicity, a genome wide screen identified two potent
suppressors, namely, djlA (encoding the membrane-bound
DNAk cochaperone DjlA) and rraA (encoding RRaA), an
inhibitor of the mRNA-degrading activity of the E. coli
RNase E (Gialama et al. 2017). E. coli strains co-expressing
djlA or rrA, referred as SuptoxD and SuptoxR, respectively,
strains were found to have a consistent behavior regarding an
enhancement production of distinct MP, namely, from mam-
malian and bacterial origin and with different topologies, and
perform better than other commercially available strains
(Gialama et al. 2017).
Another method to mitigate the toxic effect of overexpres-
sion is Brestrained expression,^ in which the production of T7
RNA polymerase and the target gene are controlled by distinct
promoters, respectively, the arabinose promoter and T7lac
promoter (Narayanan et al. 2011). Under Brestrained
expression^ conditions, namely, addition of minimal quanti-
ties of arabinose (0.01%) to produce low levels of T7 RNA
polymerase and omission of IPTG, aiming to explore the oc-
casional derepression occurring at the lac operator site of
T7lac promoter, an increase of 5- to 25-fold in the expression
of homologs of cardiac Na+/Ca2+ exchanger were obtained, in
comparison with IPTG-induction. Moreover, improvements
were also found per unit of OD600 nm of cells, indicating that
Brestrained expression^ is associated with decreased cellular
toxicity. In general, by reducing the frequency of transcription
initiation, protein production is slower, which is unlikely to
saturate the biogenesis machinery, thereby providing the ex-
planation for the decreased cytoplasmic aggregation and the
attendant cytotoxicity when comparing Brestrained^ and
Brapid^ (induction with arabinose and IPTG) expression
(Narayanan et al. 2011). Nannenga and Baneyx (2011) report-
ed the expression of MP in Δtig strains [Transcription factor
(TF) deficient] which due to TF inactivation, the signal recog-
nition particle (SRP) has unimpeded access to the nascent
transmembrane segment, thus resulting in targeting of MP to
the inner membrane, while Yidc overproduction promotesMP
insertion and folding in the lipid bilayer.
A distinct approach aiming an enhancement in the pro-
duction of soluble integral membrane spanning proteins
relied on engineering E. coli wild-type AF1000 to reduce
the growth rate/substrate uptake rate, accomplished by
d e l e t i o n s i n t h e p h o s p h o e n o l p y r u v a t e
carbohydrate:phosphotransferase system (PTS), which is
responsible for the uptake of various sugars in E. coli
(Backlund et al. 2011). Distinct mutant strains unable to
take up glucose were obtained, and characterized as fol-
lows: a defective enzyme IIABMan, which unspecifically
controls the uptake of mannose but also allows glucose
passage (ptsM); a defective enzyme IIBCGlc (ptsG), spe-
cific for glucose uptake, and the double mutant (ptsG,
ptsM). As a result of the removal of ptsG, these mutants
display a reduced growth rate at high glucose concentra-
tions but they can grow to high cell densities [although
more slowly than BL21(DE3)] since they produce no
acetic acid. In general, these strains were able to produce
some of the MP in study in relatively larger quantities
than BL21 (DE3) but whether this enhanced ability is
due to the low growth rate or the lack of acetic acid
production was not totally clarified (Backlund et al.
2011).
Finally, based on the previously published protocols used
for MP structure determination, Bruno Miroux research group
(Hattab et al. 2015) revealed the preferences of E. coli strain-
vector combinations for an optimal use of this expression
system and successful production of MP. At that time
(June 2014), they found that for the determination of 141
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unique non E. coli MP structures, 163 expression vector/
bacterial hosts were applied, from which T7 promoter was
dominant (63%), followed by the arabinose, tac, and T5
promoter-based expression systems (17%, 9%, and 7%, re-
spectively). Moreover, within T7-based expression systems,
the host BL21 (DE3) was the most employed, followed by the
mutants C43 (DE3) and C41 (DE3), accounting with 40, 18,
and 16 MP structures, respectively. Overall, this study shows
that C41 (DE3) and C43 (DE3) mutants together with the
parental host BL21 (DE3) have contributed significantly for
the success of bacterial expression systems in structural biol-
ogy of MP, in which the mutants have been preferably applied
for the production of difficult to express MP. Additional re-
marks show that IPTG concentration and growth temperature
are important parameters complementary to the choice of a
bacterial host, and that a high copy number vector should be
used with C41 (DE3) to take advantage of the strength of the
T7-based expression system, whereas for more difficult MP,
the mutant C43 (DE3), especially with low copy number plas-
mids allows to attenuate the transcription of the target gene
(Hattab et al. 2015).
Protein fusion methodologies
Aiming to increaseMP solubility and folding or to easily track
their expression levels, MP have been expressed with distinct
fusion partners (tags) such as SUMO (small ubiquitin-related
modified), MBP (maltose-binding protein), or GFP (green
fluorescent protein), synthesized either as translational (Zuo
et al. 2005; Liu et al. 2012) or transcriptional fusions (Marino
et al. 2015). In translational fusions, the N-terminal fusion
partners are part of the same protein chain of the membrane
protein and can be cleaved off after protein production if any
proteolytic cleavage site is introduced. On the other hand,
transcriptional fusions exploit the presence of an additional
RNA sequence upstream of the mRNA sequence of the target
MP, leading to a bicistronic mRNA (Marino et al. 2017). As a
result, the ribosome produces two distinct protein products
during translation, thereby eliminating the need to
enzimatically remove the fusion protein during purification
(Marino et al. 2015). As opposed to translational fusions, tran-
scriptional fusions do not lead to a physical linkage of the
fusion protein andMP, which eliminates potential interference
of the fusion partner in proper folding and functionality of the
target protein (Marino et al. 2015;Marino et al. 2017). Distinct
solubility enhancer tags such as SUMO, MBP, TrxA
(thioredoxin), or GST (glutathione-S-transferase) with sizes
ranging from 7 to 495 amino acids have been reported
(Costa et al. 2014). Based on the knowledge that ubiquitin
exerts chaperoning properties on fused proteins, translational
fusions with the ubiquitin-like protein SUMO were success-
fully explored toward an enhancement of the solubility and
biological activity of the severe acute respiratory syndrome
coronavirus (SARS-CoV) MP and 5-lipoxygenase-activating
protein (FLAP) (Zuo et al. 2005). An additional advantage is
that SUMO fusion can be cleaved with high specificity by
SUMO protease 1 and generates a protein with the native N-
terminal (Zuo et al. 2005). On the other hand, Liu et al. (2012)
evaluated different constructs resorting translational fusions of
selenoprotein K envisaging its overexpression in E. coli better
results were achievedwith cytoplasmicMBP over periplasmic
MBP and SUMO (Liu et al. 2012). In addition to the
chaperoning properties displayed by MBP and SUMO, these
fusion partners also protect the target proteins from degrada-
tion by promoting their translocation from the cytosol to the
cell membrane (MBP) and nucleus (SUMO) where less pro-
tease content exists (Costa et al. 2014). Noteworthy, beyond
an increase in the target protein solubility—solubility enhanc-
er—the natural affinity of MBP toward immobilized amylose
resins can also be explored as a purification tool; however, this
binding is highly dependent on the nature of the target protein
as it can block or reduce the amylose interaction (Costa et al.
2014). Translational fusions encompassing a solubility en-
hancer tag—MBP—and an affinity tag—His-tag—to accom-
plish the dual purpose of increasing the solubility of MPwhile
exploring their high affinity onto specific affinity chromato-
graphic matrices for purification are feasible, as previously
reported for selenoprotein K (Liu et al. 2012). A distinct strat-
egy envisaging to target proteins to E. coli inner membrane
reported by Luo et al. (2009) is based on the fusion of a novel
partner (P8CBD) to prokaryotic and eukaryotic MP. P8CBD
was carefully designed and the DNA encoding 58 amino acid
residues of E. coli Signal peptidase to provide a second trans-
membrane segment aiming to extend the protein fusion junc-
tion into the periplasmic space, which was selected based on
its ability to efficiently establish the desired orientation within
the inner membrane (Luo et al. 2009). A chitin binding do-
main was also engineered to act as an optional affinity tag or
detection epitope while at the fusion junction, an enterokinase
cleavage site and corresponding FLAG epitope were also in-
corporated. Overall, by making use of the Signal Recognition
Particle (SRP) membrane targeting pathway, the expression
and membrane translocation of P8CBD fusion proteins is en-
hanced (Luo et al. 2009). The location of translational fusions
is an important factor since they can promote different effects
when placed at the N-terminus or C-terminus (Costa et al.
2014). This is better exemplified by the attachment of affinity
oligohistidine tags to the periplasmic terminus of E. coli trans-
porters, which is detrimental for their expression (Rahman
et al. 2007). A possible explanation for this relies on a possible
interference of oligohistidine sequences with the proper trans-
location of the adjacent segments of the protein across the
membrane during biosynthesis once the charge distribution
across transmembrane segments is known to have a profound
effect on their orientation (Rahman et al. 2007). The optimum
location of the tag is also influenced by the topology of MP.
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Although Nin-Cin topologies dominate the membrane
proteomes of most organisms, one or both termini of a sub-
stantial fraction of MP are located on the extracellular or peri-
plasmic side of the membrane, for which tandem Strep-tag II
sequences or oligohistidine tags fused to MBP and a signal
sequence should be applied (Ma et al. 2015).
Unlike translational fusions, there is no need to pro-
ceed to the enzymatic removal of transcriptional tags once
there is no physical linkage between the target MP and the
fusion tag (Marino et al. 2017). Marino et al. (2015) com-
pared the expression of different proteins using transla-
tional and transcriptional fusions of genes coding for the
fusion proteins Mistic (membrane-integrating sequence
for translation of inner membrane proteins from Bacillus
subtilis), SUMO, and a shorter version of YBeL respec-
tively, mstX, sumo, and ybeL. They created bicistronic
mRNA cassettes where the stop codon of the preceding
gene (mstX, sumo, or ybeL) overlaps with the start codon
of the target protein, thereby mimicking a common genet-
ic organization observed for bacterial operons (Marino
et al. 2015). They observed an enhanced expression of
MP via transcriptional fusions with mstX and ybeL, and
the cause of this effect cannot be atributted to re-initiation
of ribosomes, but instead is most likely atributted to the
enhanced translation initiation by a more favorable sec-
ondary structure in the transcript (Marino et al. 2015).
Another major breakthrough within this field in many
expression systems was made through fusion of fluores-
cent reporters such as GFP to the target MP (Drew et al.
2001; Goehring et al. 2014; Gul et al. 2014), which be-
haves as a folding indicator of the target MP and allowing
to infer on their expression levels. This process usually
relies on fusing GFP to the C-terminal of proteins; since
GFP only becomes fluorescent if the MP integrates in the
cytoplasmic membrane, it allows to distinguish between
MP overexpression in the cytoplasmic membrane and in
inclusion bodies at any stage during overexpression, sol-
ubilization, and purification (Drew et al. 2001; Drew et al.
2006). In addition, GFP will only become fluorescent if
the MP has a Cin topology, i.e., the C-terminus is cyto-
plasmic (Drew et al. 2006). Noteworthy, fluorescence in
whole cells can be detected with a detection limit as low
as 10 μg of GFP per liter of culture, and can also be
determined in standard SDS polyacrylamide gels with a
detection limit of less than 5 ng of GFP per protein band
(Drew et al. 2006). Also, based on the use of GFP as a
fusion partner, Nji et al. (2018) recently reported a fluo-
rescence detection size exclusion chromatography-based
thermostability assay (FSEC-TS) that allows measuring
apparent melting temperatures (Tm) of MP in the absence
and presence of distinct lipids, which can be helpful to
identify which lipids can have a stabilizing effect for a
particular target.
In addition to GFP, Gul et al. (2014) reported the trans-
lational fusion of the erythromycin resistance protein (23
S ribosomal RNA adenine N-6 methyltransferase, ErmC)
(in tandem with GFP) to the C-terminus of different bac-
terial MP wherein GFP fluorescence was applied to report
the folding state of the target protein and ErmC to select
for increased expression. Evolved strains termed NG were
selected in increasing concentrations of erythromycin
which carry out a mutation in hns gene, and the degree
of MP expression correlates with the severity of hns mu-
tation, although its deletion resulted in an intermediate
expression. Overall, in each NG strain, the amount of
fluorescent (folded) protein and the ratio of folded over
misfolded protein increased up to 10-fold relative to the
parental strain BW25113B (Gul et al. 2014). Another ap-
proach to easily detect the expression levels of MP was
reported by Hsu et al. (2013) which is based on the use of
mutated bacteriorhodopsin from Haloarcula marismortui
as a fusion partner, and which unlike GFP, MP overex-
pression can be detected by naked eye or by directly mon-
itoring their optical absorption.
Aiming to select mutants of E. coli that improve MP ex-
pression, Massey-Gendel et al. (2009) reported an approach
that relies on fusing the targeted MP to a C-terminal selectable
marker that confers a drug resistance phenotype (Massey-
Gendel et al. 2009). The rationale behind this strategy is that
the production of the selectable marker and survival on selec-
tive media is linked to expression of the targeted MP, namely,
when the c-terminus is in the cytoplasm. After the selection of
the mutants, curing of isolatedmutants is performed by in vivo
digestion with the homing endonuclease I-CreI (Massey-
Gendel et al. 2009).
Recently, Mizrachi et al. (2015) developed a technique
called SIMPLEx (Solubilization of Integral MP with high
Levels of Expression), which allows the direct expression of
soluble products in living cells by fusing the target MP with
the carboxyl terminal of apolipoprotein A-1 (ApoAI*). In ad-
dition, a highly soluble Bdecoy^ protein from Borrelia
burgdorferi, namely, the outer surface protein A (MBP lack-
ing its N-terminal signal peptide can also be used) was fused
to the N-terminus to prevent the E. coli secretory pathway to
introduce the protein in inner membrane. Acting as an amphi-
pathic proteic Bshield^ which sequester MP from water,
ApoAI* promotes the solubilization of structurally diverse
MP (bitopic α-helical, polytopic α-helical, and polytopic β-
barrel) and yields of EmrE-solubilized dimers and tetramers
(EmrE basic functional units) ranged between 8 and 10 mg/L
of culture after Nickel affinity chromatography. ApoAI*-sol-
ubilized EmrE (E. coli ethidium multidrug resistance protein
E) was amenable to structural characterization including neg-
ative staining electron microscopy, dynamic light scattering,
and SAXS (Small angle X-ray scattering) data collection
(Mizrachi et al. 2015).
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Pichia pastoris
Genetic-level strategies
Yeasts and particularly P. pastoris are highly attractive alter-
natives for MP expression as they represent low-cost cultiva-
tion and high-quantity production platforms, meeting the de-
mand for criteria of safety and authentically process proteins
(Emmerstorfer-Augustin et al. 2019). Pichia pastoris systems
usually rely on the use of integrative plasmids containing the
gene of interest which are integrated into the yeast genome,
generating stable production strains (Dilworth et al. 2018).
Moreover, protein production is usually accomplished
resorting the alcohol oxidase promoter (AOX), which is in-
ducible by methanol and depending on the functionality of 1
or both aox genes, recombinant strains may present a MutS or
Mut+ phenotype exhibiting different growth behaviors (in
methanol) and different methanol requirements for induction.
Other commonly used promoter is the constitutive
glyceraldehyde-3-phosphate (GAP) dehydrogenase promoter
(Gonçalves et al. 2013; Ramón and Marín 2011).
In the last years, studies have shown that distinct recombi-
nant gene dosages and codon usage optimizations greatly in-
fluence MP expression levels in P. pastoris. As mentioned
above, P. pastoris expression systems usually rely on expres-
sion plasmids that are integrated into the yeast genome and
multi-copy clones—the so-called Bjackpot clones^—can be
selected experimentally by screening several colonies in in-
creasing concentrations of antibiotic (Dilworth et al. 2018).
Nordén et al. (2011) performed a two-step antibiotic selection,
initially with 100 μg/mL zeocin and then with higher concen-
trations, from which they isolated multi-copy clones and ob-
served that the expression of different aquaporins strongly
respond to an increase in recombinant gene dosage, indepen-
dently of the amount of protein expressed from a single gene
copy clone. However, despite higher recombinant gene dos-
ages can lead to higher titers of recombinant proteins, this
correlation is not always linear and strains with low copy
number may be preferred (Aw and Polizzi 2013; Dilworth
et al. 2018). Aiming to exclude possible false-positives while
establishing accurate correlations, along with the levels of the
target protein, the recombinant DNA levels must be evaluated,
for which qPCR protocols have been reported using pPICZ
vectors (Nordén et al. 2011) and resorting to SYBR Green or
TaqMan (Abad et al. 2010). Another way to improve human
aquaporins expression in P. pastoris is based on the optimiza-
tion of the nucleotide sequence around the initial ATG based
on the use of mammalian Kozak’s sequence consensus (Oberg
et al. 2009). The prevalence of a guanine at the first position of
the second codon after ATG encodes small amino acids such
as alanine (GCN) or on a smaller extent glycine (GGN), which
are crucial to ensure an efficient cleavage of the initiator me-
thionine (Oberg et al. 2009). In most cases, this has a positive
impact on aquaporins expression, while the opposite seems to
be observed when a thymine is at position + 6 (Oberg et al.
2009).
The codon bias problem inMP production from P. pastoris
have also been addressed. Considering that the translation
efficiency of more highly expressed genes may be especially
sensitive to codon usage, Bai et al. (2011) generated a codon
usage table specific for highly expressed genes in P. pastoris
and adjusted the sequence of P-glycoprotein-encoding mdr3
gene, taking into account relative codon frequencies for each
amino acid, as well as optimizing GC content and controlling
for mRNA instabilities. Using the optimized gene construc-
tion, the authors obtained an increase of three-fold in the ex-
pression yields in comparison with the wild-type gene of P-
glycoprotein and similar secondary and tertiary structures be-
tween the proteins from the different constructs, emphasizing
the effectiveness of the gene optimization approach developed
(Bai et al. 2011).
Expression resorting fusion partners has been applied since
the early beginning of MP expression in P. pastoris. Talmont
et al. (1996) expressed the μ-opioid receptor fused with
S. cerevisiae α-mating factor aiming to facilitate the translo-
cation of the receptor to the membrane. Distinctly, it was
shown that the presence of the α-mating factor can be detri-
mental for the expression of human histamine H1 receptor in
P. pastoris (Shiroishi et al. 2011), which can be due to incom-
plete processing by the endogenous Kex2 protease, leading to
a heterogenous population. Away to overcome this problem is
by introducing a proteolytic cleavage site upstream of the gene
(Byrne 2015).
The application of GFP as a fusion partner has been exten-
sively used to screen for high-yield expressing clones span-
ning the most popular hosts for MP production including
P. pastoris. Brooks et al. (2013) reported a fluorescent-based
induction plate assay aiming the simultaneously screening of
P. pastoris clones for the expression of aquaporin 4 and ho-
mologs of ER-associated MP phosphatidylethanolamine N-
methyltransferase inwhich 50 and 48 clones were respectively
screened. The plates were imaged under blue light and the
colony fluorescence quantified using Mean Gray Values and
revealed a distribution of fluorescence related to protein ex-
pression, ranging from background to high, being additionally
demonstrated that there is a good correlation between plate
expression and liquid culture expression (Brooks et al. 2013).
In addition to secreted proteins, MP can also enter the se-
cretory pathway but unlike them, MP remain in the ER, Golgi
or the plasma membrane (Vogl et al. 2014). Due to MP over-
expression, unfolded and misfolded proteins can accumulate
in the ER, thereby triggering the unfolded protein response
(UPR). The UPR signaling pathway involves the kinase/
RNase Ire1 that when activated, initiates an unconventional
splicing reaction of the HAC1 mRNA that ends with the re-
moval of the intron and subsequent translocation of Hac1p to
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the nucleus (Guerfal et al. 2010). Guerfal et al. (2010) showed
for the first time the beneficial effect of co-expressing Hac1p
with the adenosine A2A receptor, namely, in terms of a better
processing of the alpha-mating factor, thus improving the ho-
mogeneity of the obtained MP fractions. Later, Vogl et al.
(2014) performed a transcriptomic analysis of P. pastoris
CBS 7435 overexpressing different classes of MP (mitochon-
drial, ER/Golgi and plasma membrane localized) and found
that proteins targeted to the mitochondrial membrane mainly
alter the energy metabolism while the gene coding for Hac1p
was upregulated in strains expressing the CMP-Sialic acid
transporter, which localizes to ER and Golgi. Interestingly,
they found that the overexpression of the spliced variant of
Hac1 led to an increase of 1.5-fold to 2.1-fold in the expres-
sion of ER-resident MP tested (Vogl et al. 2014)
Strain engineering and improved processing conditions
Pichia pastoris expression strains are derivatives of NRRL-Y
11430 (Northern Regional Research Laboratories, Peoria, IL,
USA) (Cregg et al. 2000) encompassing distinct genotypes/
phenotypes, and generally, most of them have been applied for
MP production, namely, X33 (wild-type/Mut+) (Oberg et al.
2009), KM71H (arg4aox1::ARG4/MutS Arg+) (Bai et al.
2011), GS115 (his4/Mut+ His−) (Guerfal et al. 2010), and also
protease deficient strains such as SMD1163 (pep4 prb1 his4/
Mut+ His−) (André et al. 2006).
The requirement of association with cellular membranes
and the type of membranous lipids can be critical for success-
fully achieving the goal of producing a recombinant MP in a
functional active form, given their close spatial interactions
(Emmerstorfer-Augustin et al. 2019). Plasma membranes are
generally constituted by a mixture of lipids including phos-
phatidylcholine, phosphatidylethanolamine, phos-
phatidylinositol, phosphatidylserine, phosphatidic acid,
sphingolipids, and sterols (Van der Rest et al. 1995). As the
composition and molecular properties of the lipids differ from
lower to higher eukaryotes, the distinct type of sterols in yeasts
and mammalians, respectively, ergosterol and cholesterol, can
represent a bottleneck for the heterologous expression of
mammalian proteins in yeasts (Emmerstorfer-Augustin et al.
2019; Hirz et al. 2013). Therefore, aiming an improvement in
the functional expression, stability and translocation of Na+/
K+ ATPases α3β1 isoform, Hirz et al. (2013) reprogrammed
P. pastoris (strain CBS7435Δhis4Δku70) to mainly produce
cholesterol instead of ergosterol. This was accomplished by
replacing ERG6 (encodes the sterol C-24 methyl transferase)
and ERG5 (encodes the sterol C-22 desaturase) by constitu-
tive DHCR7 and DHCR24 (dehydrocholesterol reductases)
overexpression cassettes, envisaging an efficient conversion
of cholesta-5,7,24(25)-trienol to cholesterol (Hirz et al. 2013;
Emmerstorfer-Augustin et al. 2019). The authors found that
the expression levels of the target ATPase significantly
increased with induction time in the cholesterol-forming strain
compared to the wild-type strain, indicating a positive influ-
ence of the altered sterol composition on the stability of the
synthesized MP (Hirz et al. 2013). Another example of
Bhumanizing^ P. pastoris for the expression of human pro-
teins consists of the disruption of an endogenous glycosyl-
transferase gene (OCH1) and the stepwise introduction of het-
erologous glycosylation enzymes, envisaging to largely elim-
inate the fungal N-type N-glycosylation while avoiding a con-
siderable heterogeneity in the produced protein and their rapid
clearance if therapeutics is the main goal (Jacobs et al. 2009;
Laukens et al. 2015). This strategy is generally referred as
GlycoSwitch® and can be applied in wild-type strains (e.g.,
GS115) or GlycoSwitch® Man 5 strain wherein the first
glyco-engineering step was already introduced, and encom-
passes distinct glyco-engineering steps based on the transfor-
mation of P. pastoris with GlycoSwitch® vectors under pre-
viously reported protocols (Jacobs et al. 2009; Laukens et al.
2015). Currently, these vectors are commercially available
from BioGrammatics (Carlsbad, USA) under the license from
Research Corporation Technology (RCT).
Envisaging to prevent a possible inhibition of the AOX
promoter by glycerol, Pichia pastoris AOX-based
bioprocesses usually encompass an initial stage of growth in
glycerol followed by methanol induction, which is often cum-
bersome especially when glycerol consumption cannot be
monitored (Lee et al. 2017). Earlier observations with
KM71H strains demonstrating that leaky expression is not a
critical factor once the target expression per cell mass is most-
ly dependent on the starting glycerol concentration of the me-
dia and to a lesser degree by yeast nitrogen base (YNB) and
biotin concentrations. Moreover, as even in the presence of a
methanol concentration higher than the glycerol concentration
no target expression was detected until about 24 h of incuba-
tion, Lee et al. (2017) developed the Buffered extra-YNB
Glycerol Methanol (BYGM) auto-induction media (100 mM
potassium phosphate pH 6.0, 2.68% w/vYNB, 0.4% v/v glyc-
erol, 0.5% v/vmethanol and 8 × 10−5% w/v biotin). This auto-
induction method avoids the traditional media-swabbing step
and it is additionally claimed that it can be applied toMutS and
Mut+ strains and distinct MP without compromising their ex-
pression yields (Lee et al. 2017). The use of additives in cul-
ture media have also been reported to increase MP expression
levels. André et al. (2006) reported increased expression
levels of functional GPCR resorting the optimization of
growth temperature and supplementation of culture media
with specific GPCR ligands, histidine, and dimethylsulfoxide
(DMSO). As DMSO can modify the physical properties of
membranes and upregulates genes involved in lipid synthesis
(Murata et al. 2003), it can have a positive effect on MP in
yeast and is additionally pointed out that by permeabilizing
membranes, it can have an indirect effect by facilitating the
entry of other ligands to intracellular compartments where
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they reach the receptor populations (André et al. 2006). The
beneficial effect of DMSO is not restricted to GPCR as Pedro
et al. (2015) reported an increase of 1.8-fold in the enzymatic
activity of human membrane-bound catechol-O-methyltrans-
ferase (MBCOMT), achieved by adding 5% v/v DMSO.
Subsequently, the artificial neural network modelling of the
methanol induction phase, accomplished by tailoring the tem-
perature, DMSO concentration, and methanol constant flow-
rate allowed an improvement of 1.53-fold in the enzyme ac-
tivity over the best conditions performed in the DoE step
(Pedro et al. 2015). In addition, the direct solubilization of
MP whole cells (yeasts protoplasts) may help to decrease the
amount of misfolded and/or aggregated proteins that are co-
extracted with the properly folded protein (Hartmann et al.
2017).
Mammalian cell lines
General approaches and factors for successful optimization of
mammalian-based systems for recombinant protein produc-
tion have been reviewed elsewhere (Andréll and Tate 2013;
Almo and Love 2014; Hacker and Balasubramanian 2016;
McKenzie and Abbott 2018). In this sub-section, we will gen-
erally focus our attention in strategies that have been proved to
be particularly useful for MP, foreseeing improved expression
and/or folding and also those enabling biochemical and func-
tional studies of these relevant drug targets (summarized in
Table S3).
Distinct mammalian cell lines have been applied for MP
production such as HEK293, baby hamster kidney cells
(BHK-21), monkey kidney fibroblast cells (COS-7), and
CHO (Andréll and Tate 2013), but HEK293 and CHO are
more commonly applied, either in transient or stable transfec-
tion (Lyons et al. 2016).
The levels of expression of MP in transiently transfected
mammalian cell lines are affected by the plasmid size, the
amount of plasmid used per transfection, the strength of the
promoter, the cell type, the efficiency of the transfection, and
potentially, the toxicity of the transfection reagent (Andréll
and Tate 2013). Using design of experiments, Bollin et al.
(2011) optimized the yields of an antibody resorting to tran-
sient gene expression and found that the DNA concentration
can be maintained at relatively low concentrations (1 mg/L
range). Indeed, envisaging functional expression of a MP in
the plasma membrane, the ratio of plasmid DNA added per
reaction can be a crucial factor (particularly if a strong pro-
moter is used), once too much plasmid can lead to intracellular
accumulation of the protein and potentially misfolded
(Andréll and Tate 2013). Both CHO and HEK cell lines have
been extensively used in transient transfection, advances in
serum free media formulations allow their growth to high cell
densities, which can greatly facilitate the purification of target
proteins (Almo and Love 2014; McKenzie and Abbott 2018).
An alternative approach increasingly applied as a gene deliv-
ery methodology for protein production is based on the use of
lentivirus, owing to their ability to transduce a broad range of
cell types (Bandaranayake and Almo 2014). Aiming to com-
bine the ease and speed of transient transfection with the
robust expression of stable cell lines, Elegheert et al. (2018)
constructed a lentiviral plasmid suite around the transfer plas-
mid pHR-CMV-TetO2 that is designed for large-scale protein
expression from HEK293 cell lines and allows subcloning of
cDNA from the plasmid PHLsec usually applied for transient
transfection. This approach was tested in both soluble andMP,
and in general, the typical lead time for protein production
using this strategy is of 3–4 weeks and approximately three
to tenfold improvement in protein production yield per cell
was obtained, in comparison with transient transfection
(Elegheert et al. 2018).
Unlike transient transfection, stable gene expression re-
quires the screening of clonal cell lines, which is typically
achieved through limited dilution involving serial dilution of
recently transfected cells and seeding on tissue culture plates
with antibiotic-resistance media. Subsequently, different col-
onies are individually transferred to 24-well plates and scaled-
up (Andréll and Tate 2013). For a review of selection meth-
odologies, please refer to Browne and Al-Rubeai (2007).
Along the years, aiming to easily ascertain the quality and
level of expression of target MP, methodologies resorting to
GFP fusions have been reported. Particularly, the expression
of GFP fused to the termini of MP have been applied to di-
rectly monitor in whole cells for their subcellular locations by
fluorescence microscopy (Goehring et al. 2014). A slightly
different approach was reported by Mancia et al. (2004),
where the production of the target MP and GFP is based on
a bicistronic mRNA, thus leading to the production of two
separate proteins wherein the high-yielding clones are selected
based on a fluorescence-activated cell sorting procedure.
Given the relevance of MP as drug targets for a variety of
human diseases, advances in mammalian cell-based systems
have allowed performing functional studies that otherwise
could be highly hampered. Baculovirus-mediated gene trans-
duction of mammalian cells (BacMam) has been widely used
due to its compatibility with a variety of mammalian cell lines
and the possibility of co-infecting with multiple BacMam vi-
ruses to express protein complexes (Lyons et al. 2016). Shukla
et al. (2012) exploited this strategy toward the development of
a transient expression system for co-expression of two drug
transporters (ABCB1—P-glycoprotein—and ABCG2) in
mammalian cells, which is useful to determine their contribu-
tion to the transport of a common anticancer drug substrate.
Moreover, both transporters were functionally active when co-
expressed (Shukla et al. 2012). A distinct approach involves
the codon optimization of the sequence of the human sodium/
iodide symporter (NIS) based on the highest usage frequen-
cies in humans, while RNA instability motifs, very high (>
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80%) or very low (< 30%) GC content regions and cis-acting
motifs were also removed (Kim et al. 2015). As a result, the
CAI was highly improved (0.79 vs 0.97 for wild-type and
optimized sequences) and from transfected cancer cells, it
was found that the levels of NIS were enhanced as well as
the radioiodine uptake. These results show the importance of
codon usage optimizations in the development of more effi-
cient reporters and efficient therapeutic genes, distinct goals
than improving MP heterologous expression (Kim et al.
2015).
To facilitate MP production for structural analysis
relies on the use of HEK293S GnTI- (lacking the gene
N-acetylglucosaminyl transferase I—GnTI−) and a
tetracycline-inducible promoter (Chaudhary et al.
2012). If on one hand, the lack of GnTI restricts N-
linked glycans to a homogeneous Man5-GlcNac2, since
N-linked glycosylation is often regarded as a barrier
toward structure determination via X-ray crystallography
due to the heterogeneity and conformational flexibility
of these glycans, the inducible promoter allows the es-
tablishment of high-density cell cultures which are not
always achieved if the target protein tends to be cyto-
toxic (Chaudhary et al. 2012). Alternative approaches
have been suggested to overcome toxicity issues associ-
ated with MP overexpression. Ohsfeldt et al. (2012)
designed an anti-apoptosis strategy involving co-
expression of Bcl-xL gene (encodes for an anti-
apoptotic protein) aiming to prevent cell death by bio-
reactor stresses, nutrient depletion, toxin accumulation,
and stresses due to folding and processing requirements
for complex proteins such as MP. The authors observed
that cell death are diminished due to the co-expression
of the anti-apoptotic gene and transient production of
two different receptors were improved (Ohsfeldt et al.
2012).
Protein quality control
The purity and integrity of purified protein samples are usually
evaluated by electrophoresis (native or denaturant) coupled
with detection methods with varying sensitivities (Oliveira
and Domingues 2018; Raynal et al. 2014). On the other hand,
isoelectric focusing and capillary electrophoresis have also
been used to distinguish the protein of interest from closely
related undesired subproducts or contaminants (Raynal et al.
2014), while UV-Visible spectroscopy is useful to detect
nucleic acid contamination (Oliveira and Domingues 2018).
Mass spectrometry (MS) has been widely applied to mea-
sure molecular weights of proteins while allowing protein
identification by peptide mass fingerprinting (PMF) and based
on MS/MS spectra (Zhang et al. 2010). By detecting mass
changes introduced by post-translational modifications, MS
can also be used to analyze these modifications (Zhang et al.
2010). MS-compatible detection methods enable MS analysis
after electrophoresis (Raynal et al. 2014). Despite such anal-
ysis are usually performed after purification, Gan et al. (2017)
reported a nativeMS approach that allows the characterization
of overexpressed recombinant proteins directly in crude
E. coli lysates, allowing obtaining information on its identity,
solubility, oligomeric state, overall structure, and stability
without purification. Cells were lysed in a buffer supplement-
ed with 1 M ammonium acetate to ensure compatibility with
MS. Spectra were acquired for distinct proteins with molecu-
lar weights ranging from 19 to 47 kDa, and revealed highly
resolved peaks, narrow charge state distributions, and the an-
ticipated stoichiometry, thereby confirming that at least for
these proteins, purification is not a prerequisite (Gan et al.
2017).
In addition to the integrity and purity of the protein sample,
homogeneity is also crucial to infer on the correct oligomeric
structure of the protein. Dynamic light scattering (DLS) and
Fig. 2 Schematic diagram of MP
structure determination pipeline
focusing relevant parameters to
optimize their upstream stage and
techniques used to protein quality
control
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more accurately analytical size exclusion chromatography
(SEC) are useful to these determinations (Oliveira and
Domingues 2018; Raynal et al. 2014). In quality control meth-
odologies, studying the secondary and tertiary structure of
proteins is important to infer about their folding and monitor
protein conformational changes. A range of spectroscopic
techniques has been developed for such task, being circular
dichroism particularly useful to determine the secondary
structures and folding properties of recombinant proteins
(Oliveira and Domingues 2018). Based on several generic or
protein-specific functional assays which depend upon catalyt-
ic and binding properties of the protein of interest, it is also
important to determine the activity of the target protein sam-
ples (Raynal et al. 2014). Additional details of distinct analyt-
ical methods used for the characterization of therapeutic pro-
teins including advantages and drawbacks as well as the type
of information delivered from each technique can be found in
the recent review by Fuh et al. (2016).
Insights for better decision-making processes
in the upstream stage of membrane proteins
In this review, we addressed the first stage and, more specif-
ically their (bio)synthesis by recombinant production process-
es. E. coli, P. pastoris, and mammalian cell lines were select-
ed, given their wide applicability and to cover hosts with dif-
ferent inherent complexities. Based on the information here
reviewed, general insights to understand which host may bet-
ter fit in a specific project are presented in the next paragraphs
and summarized in Table 2 and Fig. 2. E. coli is probably the
better characterized host for which there are many genetic
tools available. It is more suitable for low molecular weight
MP and is capable to grow easily to high cell densities at a
relatively low cost. Unlike E. coli, mammalian cell lines allow
the production of larger MP and protein complexes with prop-
er PTM including glycosylation patterns, although in this re-
gard, the performance of mammalian cell lines is best.
However, obtaining recombinant proteins which better resem-
ble their native counterparts comes with a cost and these sys-
tems are more technically challenging and this process can be
lengthy. The methylotrophic P. pastoris gathers characteristics
from both prokaryotic and the other higher eukaryotic hosts.
Particularly, direct and indirect evidences point out the impor-
tance of P. pastoris host membranes wherein the type of lipids
can influence the expression yields and overall folding of het-
erologous human MP while inducing membrane proliferation
(HAC1 overexpression and possibly the use of DMSO as an
additive in culture media). The identification of genes limiting
MP overexpression resorting systems biology approaches
based on -omics approaches may present additional contribu-
tions to improve recombinant MP production processes in
P. pastoris.
Aiming to overcome the cellular burden caused by MP
overexpression, researchers have been driving their efforts
toward the isolation and/or engineering of host cells, which
have proven to be efficient in many cases. In addition, codon
usage optimizations have been shown to be an effective strat-
egy toward the improvement of MP expression but re-
searchers should be aware that synonymous mutations can
affect protein function. The application of fusion partners is
helpful to increase MP solubility or to easily detect their ex-
pression levels and the advent of transcriptional fusions show
that particularly for solubility-enhancing tags, it seems that a
physical linkage between target MP and fusion may not be
necessary for the desired effect, thus simplifying the overall
process.
Overall, the increasing understanding of MP biogenesis
and the host physiological response to MP recombinant pro-
duction has allowed important advances in this field.
However, while it remains difficult to set general rules for a
successful MP production process, the information gathered
in this review can help researchers with their own MP targets.
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